Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Clifford J. Bailey; Jorge L. Gross; Anne Pieters; Arnaud Bastien; James F. List

doi:10.1016/S0140-6736(10)60407-2

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Clifford J. Bailey, Jorge L. Gross, Anne Pieters, Arnaud Bastien, James F. List

Research output: Contribution to journal › Article › peer-review

Abstract

Correction of hyperglycaemia and prevention of glucotoxicity are important objectives in the management of type 2 diabetes. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption in an insulin-independent manner. We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin.

Original language	English
Pages (from-to)	2223-2233
Number of pages	11
Journal	The Lancet
Volume	375
Issue number	9733
Early online date	24 Jun 2010
DOIs	https://doi.org/10.1016/S0140-6736(10)60407-2
Publication status	Published - 26 Jun 2010

Keywords

adult
blood glucose
type 2 diabetes mellitus
double-blind method
female
glucosides
glycosylated hemoglobin A
humans
hypoglycemic agents
male
metformin
middle aged
sodium-glucose transporter 2

Access to Document

10.1016/S0140-6736(10)60407-2

Cite this

@article{f4858b4533644c189a2f4f25c59b2dfd,

title = "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial",

abstract = "Correction of hyperglycaemia and prevention of glucotoxicity are important objectives in the management of type 2 diabetes. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption in an insulin-independent manner. We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin.",

keywords = "adult, blood glucose, type 2 diabetes mellitus, double-blind method, female, glucosides, glycosylated hemoglobin A, humans, hypoglycemic agents, male, metformin, middle aged, sodium-glucose transporter 2",

author = "Bailey, {Clifford J.} and Gross, {Jorge L.} and Anne Pieters and Arnaud Bastien and List, {James F.}",

year = "2010",

month = jun,

day = "26",

doi = "10.1016/S0140-6736(10)60407-2",

language = "English",

volume = "375",

pages = "2223--2233",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9733",

}

TY - JOUR

T1 - Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin

T2 - a randomised, double-blind, placebo-controlled trial

AU - Bailey, Clifford J.

AU - Gross, Jorge L.

AU - Pieters, Anne

AU - Bastien, Arnaud

AU - List, James F.

PY - 2010/6/26

Y1 - 2010/6/26

N2 - Correction of hyperglycaemia and prevention of glucotoxicity are important objectives in the management of type 2 diabetes. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption in an insulin-independent manner. We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin.

AB - Correction of hyperglycaemia and prevention of glucotoxicity are important objectives in the management of type 2 diabetes. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption in an insulin-independent manner. We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin.

KW - adult

KW - blood glucose

KW - type 2 diabetes mellitus

KW - double-blind method

KW - female

KW - glucosides

KW - glycosylated hemoglobin A

KW - humans

KW - hypoglycemic agents

KW - male

KW - metformin

KW - middle aged

KW - sodium-glucose transporter 2

UR - http://www.scopus.com/inward/record.url?scp=77953857048&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60407-2

DO - 10.1016/S0140-6736(10)60407-2

M3 - Article

C2 - 20609968

SN - 1474-547X

VL - 375

SP - 2223

EP - 2233

JO - The Lancet

JF - The Lancet

IS - 9733

ER -

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this